Clinical safety and efficacy of a single‐dose gentamicin, posaconazole and mometasone furoate otic suspension for treatment of canine otitis externa
Veterinary Record · 04.05.2024 · 194 (9)
DOI: 10.1002/vetr.3955 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Veterinary Record, online erschienen am 10.03.2024. Verfasst von Lea Heuer und 5 weiteren Autor:innen. Beteiligte Einrichtung: MSD Animal Health Innovation, Schwabenheim an der Selz, Germany. Hauptthemen laut MEDLINE: Dog Diseases, Otitis Externa, Mometasone Furoate, Triazoles. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: MSD Animal Health Innovation.
Abstract (Originalsprache)
Background
A single‐dose, in‐clinic, veterinary professional‐administered treatment for canine otitis externa was developed to improve compliance and canine welfare.
Methods
This multicentre, controlled, examiner‐masked, randomised field trial was conducted in 316 dogs over 42 days. Dogs were treated once, on day 0, with the investigational product containing gentamicin, posaconazole and mometasone furoate (Mometamax Ultra [MU]) or twice (days 0 and 7) with a control product containing florfenicol, terbinafine and betamethasone acetate (CP). The primary endpoint was a composite otitis index score of 4 or less (of 12) on day 14 and 3 or less (of 12) on day 28.
Results
On day 28, treatment success was recorded in 128 of 143 MU‐treated dogs (89.5%), significantly non‐inferior to 116 of 133 (87.2%) CP‐treated dogs (Farrington‐Manning test, Z = 4.1351, p < 0.0001). For mixed cultures of Staphylococcus pseudintermedius and Malassezia pachydermatis , there was 100% treatment success in MU‐treated dogs ( n = 33), significantly non‐inferior to 90.2% (37 of 41) in CP‐treated dogs (Farrington–Manning test, Z = 3.1954, p = 0.0007).
Limitations
Efficacy in chronic otitis externa cases was not investigated. Cytology was not used to aid in diagnosis or for identification of secondary pathogens.
Conclusion
This unique combination, single‐dose product is safe and effective in dogs with otitis externa. It offers enhanced compliance, canine welfare and quality of life by eliminating the owner burden of treating this painful condition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- MSD Animal Health Innovation, Schwabenheim an der Selz, Germany.
- Cebiphar, Fondettes, France.
- Löhlein & Wolf Vet Research and Consulting, München, Germany.
Förderung
- MSD Animal Health Innovation
Zitieren
APA
Heuer, L., Wilhelm, C., Roy, O., Löhlein, W., Wolf, O., & Zschiesche, E. (2024). Clinical safety and efficacy of a single‐dose gentamicin, posaconazole and mometasone furoate otic suspension for treatment of canine otitis externa. Veterinary Record, 194(9). https://doi.org/10.1002/vetr.3955
Vancouver
Heuer L, Wilhelm C, Roy O, Löhlein W, Wolf O, Zschiesche E. Clinical safety and efficacy of a single‐dose gentamicin, posaconazole and mometasone furoate otic suspension for treatment of canine otitis externa. Veterinary Record. 2024;194(9). doi:10.1002/vetr.3955
BibTeX
@article{Heuer2024,
author = {Heuer, Lea and Wilhelm, Cornelia and Roy, Olivier and Löhlein, Wolfgang and Wolf, Oliver and Zschiesche, Eva},
title = {Clinical safety and efficacy of a single‐dose gentamicin, posaconazole and mometasone furoate otic suspension for treatment of canine otitis externa},
journal = {Veterinary Record},
year = {2024},
volume = {194},
number = {9},
doi = {10.1002/vetr.3955}
}
EUVIMED